Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis ; volume:16 ; number:5 ; day:18 ; month:9 ; year:2014 ; pages:1-12 ; date:10.2014
Arthritis Research & Therapy ; 16, Heft 5 (18.9.2014), 1-12, 10.2014
- Urheber
-
Nagai, Toshihiro
- Beteiligte Personen und Organisationen
-
Sato, Masato
Kobayashi, Miyuki
Yokoyama, Munetaka
Tani, Yoshiki
Mochida, Joji
SpringerLink (Online service)
- DOI
-
10.1186/s13075-014-0427-y
- URN
-
urn:nbn:de:1111-201605191242
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:48 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nagai, Toshihiro
- Sato, Masato
- Kobayashi, Miyuki
- Yokoyama, Munetaka
- Tani, Yoshiki
- Mochida, Joji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
Anti-Vascular Endothelial Growth Factor (Bevacizumab) Therapy Reduces Hypertrophic Scar Formation in a Rabbit Ear Wounding Model
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis
PDK4 inhibits osteoarthritis progression by activating the PPAR pathway
Bevacizumab suppressed degenerative changes in articular cartilage explants from patients with osteoarthritis of the knee
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization
The paracrine effect of adipose-derived stem cells inhibits osteoarthritis progression
Carbon monoxide inhibits Fas activating antibody-induced apoptosis in endothelial cells
Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
Anti-Vascular Endothelial Growth Factor (Bevacizumab) Therapy Reduces Hypertrophic Scar Formation in a Rabbit Ear Wounding Model
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis
PDK4 inhibits osteoarthritis progression by activating the PPAR pathway
Bevacizumab suppressed degenerative changes in articular cartilage explants from patients with osteoarthritis of the knee
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization
The paracrine effect of adipose-derived stem cells inhibits osteoarthritis progression
Carbon monoxide inhibits Fas activating antibody-induced apoptosis in endothelial cells
Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
Anti-Vascular Endothelial Growth Factor (Bevacizumab) Therapy Reduces Hypertrophic Scar Formation in a Rabbit Ear Wounding Model
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis
PDK4 inhibits osteoarthritis progression by activating the PPAR pathway
Bevacizumab suppressed degenerative changes in articular cartilage explants from patients with osteoarthritis of the knee
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization
The paracrine effect of adipose-derived stem cells inhibits osteoarthritis progression